IGCS 2024 Endometrial Cancer Master Session-Part 2

Video Transcription

Video Summary

The session focused on advancements and challenges in the treatment of endometrial cancer, particularly with new therapies like immunotherapy and chemotherapy. The speakers, Mansoor Mirza, Anna Wachnin, Nicoletta Colombo, Erbel Collins, and Christina Lindeman, discussed evolving treatment protocols and clinical trials. Nicoletta Colombo highlighted the importance of understanding different subtypes of endometrial cancer, pointing out that molecular classification now defines treatment paths. Apart from traditional radiotherapy and chemotherapy, the panel discussed immune checkpoint inhibitors, especially for the DMMR (deficient mismatch repair) subgroup, which shows substantial benefits from immunotherapy. <br /><br />The speakers examined significant trials like RUBY, ATEN, and DUO-A, emphasizing the effectiveness of adding immunotherapy to typical chemotherapy, particularly for improving progression-free survival and overall survival. The integration of PARP inhibitors with immunotherapy was also reviewed, though determining the most effective patient subgroups for this combination remains ongoing. Discussions included optimizing treatment duration and cost-effectiveness, especially considering the high financial burden of therapies and the differential access globally.<br /><br />Christina Lindeman addressed managing side effects of immunotherapy, stressing the necessity of early detection and intervention for adverse effects. The session concluded with audience interaction, raising key concerns about therapy accessibility, cost, and practical implementation in varied healthcare systems. The exchange underscored the need for ongoing research, policy advocacy for equitable drug access, and tailoring treatment based on individual patient profiles.

Keywords

endometrial cancer

immunotherapy

chemotherapy

molecular classification

immune checkpoint inhibitors

clinical trials

PARP inhibitors

treatment protocols

therapy accessibility

side effects management